Kirsten Sadler Edepli
- ASSOCIATE PROFESSOR Medicine, Liver Diseases
- ASSOCIATE PROFESSOR Developmental and Regenerative Biology
B.A., Mount Holyoke College
M.M.Sc., Harvard Medical School
Ph.D., Harvard University
fellowship, Massachusetts Institute of Technology
- Our laboratory studies the epigenetic regulation of liver development and liver cancer and the relationship between ER stress, the unfolded protein response and fatty liver disease. We use zebrafish, cell biological and genomic approaches to uncover the fundamental biological processes that govern these phenotypes. For detailed information, please consult our lab website.
The Sadler laboratory belongs to:
The Department of Developmental and Regenerative Biology
The Department of Medicine/Division of Liver Diseases
Training areas in Development and Stem Cell Biology, Cancer Biology and Genetics and Genomics
The Mount Sinai Zebrafish Facility is managed by Dr. Sadler.
Harold and Golden Lamport Award
Mount Sinai School of Medicine
2008 - 2011
Basil O'Connor Starter Scholar Award
March of Dimes
2008 - 2011
Research Scholar Award
American Gastroenterological Association
Dr. Sadler-Edepli is the Director of the Zebrafish Models of Liver Disease Laboratory and the Model Co-Core Director of the Mount Sinai Alcoholic Liver Disease Research Center.
Specific Clinical/Research Interest: Using zebrafish to understand liver development, regeneration and disease.
Students: Brandon Kent (co-mentored with Dr. Martin Walsh)
Postdoctoral Fellows: Yelena Chernyavskay, Chi Zhang
Research Personnel: Ruhina Rafiq, Patrick Bradley (Zebrafish Facility manager)
Faculty: Jaime Chu, M.D.
Current Research Focus
Using zebrafish to understand liver development, regeneration and disease
Zebrafish are an excellent model for studying embryonic development and we are using the power of zebrafish genetics to define genes required for liver growth as well as to identify new models of liver diseases. Fatty liver disease is emerging as an important liver pathology and is typically associated with obesity and type II diabetes and together these comprise Metabolic Syndrome, which affects nearly 5 percent of the American population. We have found a zebrafish mutant that develops fatty liver disease in the embryo, and have named it foie gras (foiegr). The foie gras gene is well conserved in animals, and has recently been shown to be a component of the TRAPP complex (trappc11) which functions to tether vesicles in the secretory pathway to their destination compartment. We found that there is significant activation of the unfolded protein response (UPR) in foigr/trappc11 mutants and that in zebrafish, as in mammals, robust UPR induction is sufficient to cause fatty liver disease. Research in the Sadler lab focuses on understanding the relationship between UPR activation and fatty liver disease, understanding the cellular function of foiegr/trappc11, and using the zebrafish bearing a mutation in the foiegr gene as a model for studying fatty liver disease.
The second focus of our lab is to determine the epigenetic basis for liver growth in the embryo and during the development of liver cancer by focusing on the epigenetic regulator, UHRF1. This gene is required for DNA methylation and wehave found that loss of uhrf1 this contributes to a cell cycle defect and apoptosis which prevents hepatic outgrowth in zebrafish embryos. Additionally, UHRF1 is an oncogene in liver cancer and overexpression of UHRF1 in hepatocytes causes DNA hypomethylation and senescence and then when senescence is bypassed, tumors form.
Current Research Studies
- Investigating the role of the unfolded protein response (UPR) in fatty liver disease
- Elucidating the cellular function of Foigr/Trappc11.
- Understanding the role of UHRF1 in regulating the epigenetic basis of liver growth in embryos, regeneration in adults and liver cancer.
- Determining how senescence bypass occurs in epigenetically damaged cells to give rise to cancer.
Mudbhary R, Hoshida Y, Chernyavskaya Y, Jacob V, Villanueva A, Fiel MI, Chen X, Kojima K, Thung S, Bronson RT, Lachenmayer A, Revill K, Alsinet C, Sachidanandam R, Desai A, SenBanerjee S, Ukomadu C, Llovet JM, Sadler KC. UHRF1 overexpression drives DNA hypomethylation and hepatocellular carcinoma. Cancer cell 2014 Feb; 25(2).
Vacaru A, Di Narzo AF, Howarth DL, Tsedensodnom O, Imrie D, Cinaroglu A, Amin S, Hao K, Sadler KC. Molecularly defined unfolded protein response subclasses have distinct correlations with fatty liver disease in zebrafish. Disease Models and Mechanisms 2014; 7(7): 823-35.
Howarth DL, Lindtner C, Vacaru AM, Sachidanandam R, Tsedensodnom O, Vasilkova T, Buettner C, Sadler KC. Activating transcription factor 6 is necessary and sufficient for alcoholic fatty liver disease in zebrafish. PLoS genetics 2014 May; 10(5).
Vacaru AM, Unlu G, Spitzner M, Mione M, Knapik EW, Sadler KC. In vivo cell biology in zebrafish - providing insights into vertebrate development and disease. Journal of cell science 2014 Feb; 127(Pt 3).
Tsedensodnom O, Vacaru AM, Howarth DL, Yin C, Sadler KC. Ethanol metabolism and oxidative stress are required for unfolded protein response activation and steatosis in alcoholic liver disease. Disease models & mechanisms 2013; 6(5): 1213.
Cinaroglu A, Gao C, Imrie D, Sadler KC. Activating transcription factor 6 plays protective and pathological roles in steatosis due to endoplasmic reticulum stress in zebrafish. Hepatology (Baltimore, Md.) 2011 Aug; 54(2).
Chu J, Loughlin EA, Gaur NA, SenBanerjee S, Jacob V, Monson C, Kent B, Oranu A, Ding Y, Ukomadu C, Sadler KC. UHRF1 phosphorylation by cyclin A2/cyclin-dependent kinase 2 is required for zebrafish embryogenesis. Molecular biology of the cell 2012 Jan; 23(1).
Passeri M, Cinaroglu A, Gao C, Sadler KC. Hepatic Steatosis in Response to Acute Alcohol Exposure in Zebrafish Depends Upon SREBP Activation. Hepatology 2008; 49.
Sadler KC, Krahn KN, Gaur NA, Ukomadu C. Liver growth in the embryo and during liver regeneration in zebrafish requires the cell cycle regulator, uhrf1. Proc Natl Acad Sci U S A 2007; 104: 1570-1575.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Sadler Edepli did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.
Annenberg Building Floor 25 Room 25-26B (office); 30 (lab)
1468 Madison Avenue
New York, NY 10029
Annenberg Building Floor 25 Room 25-30 (lab);
1468 Madison Avenue
New York, NY 10029